Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease
Progressive multifocal leukoencephalopathy (PML) is a devastating CNS infection caused
by JC virus (JCV), a polyomavirus that commonly establishes persistent, asymptomatic …
by JC virus (JCV), a polyomavirus that commonly establishes persistent, asymptomatic …
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain
MW Ferenczy, LJ Marshall, CDS Nelson… - Clinical microbiology …, 2012 - Am Soc Microbiol
Progressive multifocal leukoencephalopathy (PML) is a debilitating and frequently fatal
central nervous system (CNS) demyelinating disease caused by JC virus (JCV), for which …
central nervous system (CNS) demyelinating disease caused by JC virus (JCV), for which …
The human JC polyomavirus (JCPyV): virological background and clinical implications
HH Hirsch, P Kardas, D Kranz, C Leboeuf - Apmis, 2013 - Wiley Online Library
JC polyomavirus (JCPyV) was the first of now 12 PyVs detected in humans, when in 1964,
PyV particles were revealed by electron microscopy in progressive multifocal …
PyV particles were revealed by electron microscopy in progressive multifocal …
Persistence and pathogenesis of the neurotropic polyomavirus JC
HS Wollebo, MK White, J Gordon, JR Berger… - Annals of …, 2015 - Wiley Online Library
Many neurological diseases of the central nervous system (CNS) are underpinned by
malfunctions of the immune system, including disorders involving opportunistic infections …
malfunctions of the immune system, including disorders involving opportunistic infections …
The biology of JC polyomavirus
B Assetta, WJ Atwood - Biological chemistry, 2017 - degruyter.com
JC polyomavirus (JCPyV) is the causative agent of a fatal central nervous system
demyelinating disease known as progressive multifocal leukoencephalopathy (PML). PML …
demyelinating disease known as progressive multifocal leukoencephalopathy (PML). PML …
Natalizumab treatment perturbs memory‐and marginal zone‐like B‐cell homing in secondary lymphoid organs in multiple sclerosis
R Planas, I Jelc̆ić, S Schippling… - European journal of …, 2012 - Wiley Online Library
Natalizumab, an antibody against the α4 subunit of α4 integrins, has been approved for
multiple sclerosis (MS) therapy based on its high efficacy and safety profile. However …
multiple sclerosis (MS) therapy based on its high efficacy and safety profile. However …
New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy
A Bellizzi, E Anzivino, DM Rodio… - Journal of …, 2013 - Wiley Online Library
John Cunningham virus (JCV) is a member of the Polyomaviridae family. It was first isolated
from the brain of a patient with Hodgkin disease in 1971, and since then the etiological …
from the brain of a patient with Hodgkin disease in 1971, and since then the etiological …
Human polyomavirus reactivation: disease pathogenesis and treatment approaches
CF De Gascun, MJ Carr - Journal of Immunology Research, 2013 - Wiley Online Library
JC and BK polyomaviruses were discovered over 40 years ago and have become
increasingly prevalent causes of morbidity and mortality in a variety of distinct …
increasingly prevalent causes of morbidity and mortality in a variety of distinct …
Innovative therapeutic concepts of progressive multifocal leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral disease of the
brain—caused by human polyomavirus 2. It affects patients whose immune system is …
brain—caused by human polyomavirus 2. It affects patients whose immune system is …
Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird's eye view
EA Mills, Y Mao-Draayer - Frontiers in Immunology, 2018 - frontiersin.org
The increased use of newer potent immunomodulatory therapies for multiple sclerosis (MS),
including natalizumab, fingolimod, and dimethyl fumarate, has expanded the patient …
including natalizumab, fingolimod, and dimethyl fumarate, has expanded the patient …